scholarly journals Characterization of the Fecal Microbiota in Gastrointestinal Cancer Patients and Healthy Controls

2020 ◽  
Author(s):  
Ningning Li ◽  
Chunmei Bai ◽  
Yuanzhi Guan ◽  
Lin Zhao ◽  
Yuping Ge ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Gastric Cancer ◽  
Gut Microbiota ◽  
Cancer Patients ◽  
Gastrointestinal Cancer ◽  
Fecal Microbiota ◽  
Gastrointestinal Tumors ◽  
Control Group ◽  
Fecal Bacteria ◽  
Healthy Controls

Abstract Background The incidence and mortality of gastrointestinal tumors are high in China. Some studies suggested that the gut microbiota is also related to the occurrence and development of tumors. At present, there are no prospective studies based on the correlation between gastrointestinal tumors and gut microbiota in the Chinese population. The objective of this report is to characterize the fecal microbiota in patients with esophageal cancer, gastric cancer, and colorectal cancer and healthy controls. Methods Patients with locally advanced or metastatic esophageal, gastric, and colorectal cancer were enrolled, and healthy people were included as controls. 16S rRNA sequencing was used to analyze the characteristics of fecal microbiota. PICRUSt software was used for functional prediction.Results Significant differences in the composition and abundance of fecal microbiota were identified between gastrointestinal cancer patients and healthy controls. The abundance of F. prausnitzii, C. clostridioforme, and B. adolescents in three different tumor groups was all significantly lower than in the control group (P<0.05). The abundance of R. gnavus, B. obeum, and R. faecis in the gastric and colorectal cancer groups was significantly lower than in the control group (P<0.05). The abundance of Dorea in the gastric cancer group was significantly lower than in the control group (P<0.05). B. fragilis, P. corpi, and E. coli were overabundant in the different tumor groups compared with the control (P<0.05). There were significant differences in functional metabolism and cell biological function between the tumor and control groups (P<0.05). The feces of cancer patients with more advanced staging had higher abundance of Prevotella and fewer Clostridium. Conclusions Patients with esophageal or gastric cancer had similar features of fecal bacteria as those with colorectal cancer. The metabolic function of fecal bacteria in the gastrointestinal cancer patients and the healthy controls were different.

scholarly journals Study of the Relationship between Microbiome and Colorectal Cancer Susceptibility Using 16SrRNA Sequencing

2020 ◽  
Vol 2020 ◽  
pp. 1-17 ◽  
Author(s):  
Wanxin Liu ◽  
Ren Zhang ◽  
Rong Shu ◽  
Jinjing Yu ◽  
Huan Li ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Gut Microbiota ◽  
Cancer Susceptibility ◽  
Precancerous Lesions ◽  
Bacterial Community Composition ◽  
Intestinal Flora ◽  
Control Group ◽  
Healthy Controls ◽  
Healthy Individuals

A lot of previous studies have recently reported that the gut microbiota influences the development of colorectal cancer (CRC) in Western countries, but the role of the gut microbiota in Chinese population must be investigated fully. The goal of this study was to determine the role of the gut microbiome in the initiation and development of CRC. We collected fecal samples of 206 Chinese individuals: 59 with polyp (group P), 54 with adenoma (group A), 51 with colorectal cancer (group CC), and 42 healthy controls (group HC).16S ribosomal RNA (rRNA) was used to compare the microbiota community structures among healthy controls, patients with polyp, and those with adenoma or colorectal cancer. Our study proved that intestinal flora, as a specific indicator, showed significant differences in its diversity and composition. Sobs, Chao, and Ace indexes of group CC were significantly lower than those of the healthy control group (CC group: Sobs, Chao, and Ace indexes were 217.3 ± 69, 4265.1 ± 80.7, and 268.6 ± 78.1, respectively; HC group: Sobs, Chao, and Ace indexes were 228.8 ± 44.4, 272.9 ± 58.6, and 271.9 ± 57.2, respectively). When compared with the healthy individuals, the species richness and diversity of intestinal flora in patients with colorectal cancer were significantly reduced: PCA and PCoA both revealed that a significant separation in bacterial community composition between the CC group and HC group (with PCA using the first two principal component scores of PC1 14.73% and PC2 10.34% of the explained variance, respectively; PCoA : PC1 = 14%, PC2 = 9%, PC3 = 6%). Wilcox tests was used to analyze differences between the two groups, it reveals that Firmicutes (P=0.000356), Fusobacteria (P=0.000001), Proteobacteria (P=0.000796), Spirochaetes (P=0.013421), Synergistetes (P=0.005642) were phyla with significantly different distributions between cases and controls. The proportion of microorganism composition is varying at different stages of colon cancer development: Bacteroidetes (52.14%) and Firmicutes (35.88%) were enriched in the healthy individuals; on the phylum level, the abundance of Bacteroidetes (52.14%-53.92%-52.46%–47.06%) and Firmicutes (35.88%-29.73%-24.27%–25.36%) is decreasing with the development of health-polyp-adenomas-CRC, and the abundance of Proteobacteria (9.33%-12.31%-16.51%–22.37%) is increasing. PCA and PCOA analysis showed there was no significant (P<0.05) difference in species similarity between precancerous and carcinogenic states. However, the composition of the microflora in patients with precancerous lesions (including patients with adenoma and polyp) was proved to have no significant disparity (P<0.05). Our study provides insights into new angles to dig out potential biomarkers in diagnosis and treatment of colorectal cancer and to provide scientific advice for a healthy lifestyle for the sake of gut microbiota.

scholarly journals Association and diagnostic value of serum SPINK4 in colorectal cancer

PeerJ ◽  
2019 ◽  
Vol 7 ◽  
pp. e6679 ◽  
Author(s):  
Mingzhi Xie ◽  
Kezhi Li ◽  
Jilin Li ◽  
Dongcheng Lu ◽  
Bangli Hu
Keyword(s):  
Colorectal Cancer ◽  
Gastric Cancer ◽  
Cancer Patients ◽  
Characteristic Curve ◽  
Disease Free Survival ◽  
Diagnostic Value ◽  
Healthy Controls ◽  
Significant Difference ◽  
Peptidase Inhibitor ◽  
Gastric Cancer Patients

The role of serum serine peptidase inhibitor, Kazal type 4 (SPINK4), in colorectal cancer (CRC) is largely unknown. This study aimed to explore the association and diagnostic value of serum SPINK4 in CRC. A total of 70 preoperative CRC patients, 30 postoperative CRC patients, 30 gastric cancer patients, and 30 healthy controls were enrolled. Using enzyme-linked immunosorbent assays, we found that the serum SPINK4 level was significantly increased in preoperative CRC compared with postoperative CRC patients, gastric cancer patients, and healthy controls (p < 0.05). The serum SPINK4 level was remarkably elevated in colon cancer compared with rectal cancer and was enhanced in the M1 stage compared with the M0 stage (p < 0.05). The area under the receiver operating characteristic curve of serum SPINK4 level in the diagnosis of CRC was 0.9186, with a sensitivity and specificity of 0.886 and 0.900, respectively, and a cut-off value of 2.065. There was no significant difference between high and low expression of serum SPINK4 regarding the overall survival time and disease-free survival (p > 0.05). This study demonstrated that the serum SPINK4 level increased in CRC and was associated with the location and distant metastasis of CRC. It had a high diagnostic value in CRC but was not associated with the survival of CRC patients.

scholarly journals Quantitative Analysis of Methylated Adenosine Modifications Revealed Increased Levels of N6-Methyladenosine (m6A) and N6,2′-O-Dimethyladenosine (m6Am) in Serum From Colorectal Cancer and Gastric Cancer Patients

2021 ◽  
Vol 9 ◽  
Author(s):  
Yiqiu Hu ◽  
Zhihao Fang ◽  
Jiayi Mu ◽  
Yanqin Huang ◽  
Shu Zheng ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Gastric Cancer ◽  
Quantitative Analysis ◽  
Early Detection ◽  
Human Serum ◽  
Cancer Patients ◽  
Healthy Controls ◽  
Serum Samples ◽  
Gastrointestinal Malignancies ◽  
Gastric Cancer Patients

Colorectal cancer and gastric cancer are the most prevalent gastrointestinal malignancies worldwide, and early detection of these cancers is crucial to reduce their incidence and mortality. RNA methylation plays an important regulatory role in a variety of physiological activities, and it has drawn great attention in recent years. Methylated adenosine (A) modifications such as N6-methyladenosine (m6A), N1-methyladenosine (m1A), 2′-O-methyladenosine (Am), N6,2′-O-dimethyladenosine (m6Am), and N6,N6-dimethyladenosine (m62A) are typical epigenetic markers of RNA, and they are closely correlated to various diseases including cancer. Serum is a valuable source of biofluid for biomarker discovery, and determination of these adenosine modifications in human serum is desirable since they are emerging biomarkers for detection of diseases. In this work, a targeted quantitative analysis method using hydrophilic interaction liquid chromatography–tandem mass spectrometry (HILIC-MS/MS) was developed and utilized to analyze these methylated adenosine modifications in serum samples. The concentration differences between the healthy volunteers and cancer patients were evaluated by Mann–Whitney test, and receiver operator characteristic (ROC) curve analysis was performed to access the potential of these nucleosides as biomarkers. We demonstrated the presence of the m6Am in human serum for the first time, and we successfully quantified the concentrations of A, m6A, m1A, and m6Am in serum samples from 99 healthy controls, 51 colorectal cancer patients, and 27 gastric cancer patients. We found that the levels of m6A and m6Am in serum were both increased in colorectal cancer or gastric cancer patients, compared to that in healthy controls. These results indicate that m6A and m6Am in serum may act as potential biomarkers for early detection and prognosis of colorectal cancer and gastric cancer. In addition, the present work will stimulate investigations on the effects of adenosine methylation on the initiation and progression of colorectal cancer and gastric cancer.

scholarly journals Prevalence and Risk Factors of Gastric Adenoma and Gastric Cancer in Colorectal Cancer Patients

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Dae Hyun Tak ◽  
Hee Seok Moon ◽  
Sun Hyung Kang ◽  
Jae Kyu Sung ◽  
Hyun Yong Jeong
Keyword(s):  
Colorectal Cancer ◽  
Gastric Cancer ◽  
Cancer Patients ◽  
Patient Group ◽  
Gastrointestinal Endoscopy ◽  
Control Group ◽  
Upper Gastrointestinal Endoscopy ◽  
Gastric Adenoma ◽  
Colorectal Cancer Patients ◽  
Upper Gastrointestinal

Background/Aims. To evaluate the incidence of gastric adenoma and gastric cancer in colorectal cancer patients, as well as the clinicopathological features that affect their incidence.Methods. Among patients who underwent surgery after being diagnosed with colorectal cancer between January 2004 and December 2013 at Chungnam National University Hospital, 142 patients who underwent follow-up upper gastrointestinal endoscopy were assigned to the patient group. The control group included 426 subjects randomly selected. The patient group was subdivided into two: one that developed gastric adenoma or cancer and one that did not. Clinicopathological characteristics were compared between these groups.Results. In total, 35 (24.6%) colorectal cancer patients developed a gastric adenoma or gastric cancer, which was higher than the number in the control group (20 [4.7%] patients;p<0.001). Age, alcohol history, and differentiation of colorectal cancer were associated with higher risks of gastric adenoma or gastric cancer, with odds ratios of 1.062, 6.506, and 5.901, respectively.Conclusions. In colorectal cancer patients, screening with upper gastrointestinal endoscopy is important, even if no lesions are noted in the upper gastrointestinal tract at colorectal cancer diagnosis. Endoscopic screening is particularly important with increasing age, history of alcohol consumption, and poor cancer differentiation.

scholarly journals Increasing serum level of transforming growth factor beta 2 (TGF-β) in patients with colorectal and gastric cancer in Iraq

2013 ◽  
Vol 7 (1) ◽  
pp. 72-79
Author(s):  
Ahmed Rushdi Abdullah ◽  
Shaimaa Yousif Abdulfattah ◽  
Farah Thamer Abdullah ◽  
Ali Talib Abid ◽  
Hussam Bassim Salah
Keyword(s):  
Colorectal Cancer ◽  
Gastric Cancer ◽  
Serum Level ◽  
Cancer Patients ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Control Group ◽  
Healthy Control ◽  
Growth Factor Beta ◽  
Gastric Cancer Patients

Gastrointestinal cancers (GITs) are worldwide problem particularly in highly developed countries. In Iraq, gastric cancer(GC) is the 9th most common cancer while colorectal cancers (CRC) is considered as the 7th most common cancer among all cancer patients in both males and females. The Objective of this study was to estimate the serum level of transforming growth factor beta 2 (TGF-β) in Iraqi patients who are complying from gastric and colorectal cancers. Fifty four serum samples were collected starting from the 1st of March till the mid of May of 2011 to investigate the TGF-β serum level by using ELISA technique. Thirty eight samples were gastric (H.pylori +ve) and colorectal cancer patients (GC=17, CRC=21) while the other 16 samples considered as a healthy control group. The results showed that TGF-β serum levels of both GIT tumors were increased significantly (p<0.05) compared to the healthy control group. In conclusion, the presented study showed elevated serum level of TGF-β in Gastric cancer patients which could point out to use this elevation as a biomarker for tumor prognosis; while in colorectal cancer it may evade the immune system cancer killing mechanisms. We recommend further studies concerning the correlation between serum level of TGF-β in Gastric cancer patients with staging and grading, and more immunological techniques can be implied to know the exact immunological evading mechanism of colorectal cancer cells.

scholarly journals Fecal microbiota profile in patients with inflammatory bowel disease in Taiwan

2020 ◽  
Author(s):  
Tien-En Chang ◽  
Jiing-Chyuan Luo ◽  
Ueng-Cheng Yang ◽  
Yi-Hsiang Huang ◽  
Ming-Chih Hou ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Gut Microbiota ◽  
Bowel Disease ◽  
Structural Difference ◽  
Fecal Microbiota ◽  
Control Group ◽  
Sequence Variant ◽  
Healthy Controls ◽  
Significant Difference ◽  
Inflammatory Bowel

Abstract Background Inflammatory bowel disease (IBD) is a chronic inflammatory disease that associated with complicated interaction between immune, gut microbiota and environmental factors in a genetically vulnerable host. Dysbiosis is often seen in patients with IBD. Our aim is to investigate the fecal microbiota in patients with IBD and compared to healthy controls in Taiwan. Methods In this cross-sectional study, we investigated fecal microbiota in 20 patients with IBD and 48 healthy controls. Fecal samples from both IBD patients and controls were analyzed by next-generation sequencing method and relevant software. Results The IBD group showed lower bacterial richness and diversity compared to the control group. The principal coordinate analysis also revealed significant structural difference between the IBD group and the control group. These findings were consistent whether the analysis was based on operational taxonomic unit or amplicon sequence variant. However, no significant difference was found when comparing the composition of fecal microbiota between ulcerative colitis (UC) and Crohn’s disease (CD). Further analysis showed that Lactobacillus, Enterococcus, Bifidobacterium and Veillonella were dominant in the IBD group, while Faecalibacterium and Subdoligranulum were dominant in the control group at genus level. When comparing UC, CD and control group, Lactobacillus, Bifidobacterium and Enterococcus were identified as dominant genera in the UC group. Fusobacterium and Escherichia_Shigella were dominant in the CD group. Faecalibacterium and Subdoligranulum were dominant in the control group. Conclusions Compared to the healthy control, the IBD group showed dysbiosis with a significant decreased in both richness and diversity of gut microbiota.

scholarly journals Serum microRNA-135a-5p as an auxiliary diagnostic biomarker for colorectal cancer

2016 ◽  
Vol 54 (1) ◽  
pp. 76-85 ◽  
Author(s):  
Qinjun Wang ◽  
Hongchun Zhang ◽  
Xianjuan Shen ◽  
Shaoqing Ju
Keyword(s):  
Colorectal Cancer ◽  
Carcinoembryonic Antigen ◽  
Cancer Patients ◽  
Carbohydrate Antigen ◽  
Colorectal Polyps ◽  
Control Group ◽  
Healthy Controls ◽  
Relative Expression ◽  
Serum Carcinoembryonic Antigen ◽  
Colorectal Cancer Patients

Objective The purpose of this study was to explore serum miR-135a-5p expression in colorectal cancer and examine the potential usefulness of this molecule as a biomarker for diagnosis in colorectal cancer. Methods Serum samples were collected from 60 patients with primary colorectal cancer, 40 patients with colorectal polyps and 50 healthy controls. Serum miR-135a-5p expression levels were detected by reverse transcription quantitative real-time quantitative polymerase chain reaction. Serum carcinoembryonic antigen and carbohydrate antigen 199 concentrations were detected by MODULAR ANALYTICS E170. Results The relative expression level of serum miR-135a-5p in colorectal cancer patients, colorectal polyps patients and healthy controls was 2.451 (1.107, 4.413), 0.946 (0.401, 1.942) and 0.949 (0.194, 1.415), respectively, indicating that it was significantly higher in colorectal cancer patients than that in the other two groups ( U = 351.0, 313.0, both P < 0.001). Additionally, it was significantly correlated with different degrees of tumour differentiation ( U = 215.0, P = 0.029) and different tumour stages ( U = 202.0, P = 0.013). There was no significant correlation between the relative expression of serum miR-135a-5p and carcinoembryonic antigen ( r2 = 0.023, P = 0.293) or carbohydrate antigen 199 ( r2 = 0.067, P = 0.068) in colorectal cancer patients. Compared with colorectal polyps group, AUCROC of serum miR-135a-5p in colorectal cancer group was 0.832 with 95% CI 0.73–0.93; compared with healthy control group, AUCROC was 0.875 with 95% CI 0.80–0.95. Conclusion Serum miR-135a-5p expression in colorectal cancer patients was higher than that in patients with colorectal polyps and healthy controls, suggesting that serum miR-135a-5p may prove to be an important biomarker for auxiliary diagnosis of colorectal cancer.

Sign in / Sign up

Export Citation Format

Share Document